An increasingly busy ministerial agenda risks squeezing out other issues

The health debate is increasingly shifting ahead of the election, mainly to challenging issues, including the fierce debate impacting the private health sector. What does it mean for stakeholders wanting attention in other areas? A welcome decision to widen access to a vaccine, but the postcode lottery remains a reality for patients, including babies.

Better Access Australia and AusPIPS Inc have welcomed the expanded funded access via the National Immunisation Program to GSK's shingles vaccine, Shingrix, to include immunocompromised patients.

CSL has announced the sale of its Wuhan Zhong Yuan Rui De Biologicals Products plasma collection and fractionation operations to Chengdu Rongsheng Pharmaceutical for USD$185 million in cash proceeds.

NACCHO has announced the recipients of the 2024 Aboriginal and Torres Strait Islander Pharmacy Leadership Grant, which is supported by Pfizer.

The Federal Government is continuing to negotiate a First Pharmaceutical Wholesaler Agreement with the National Pharmaceutical Services Association.

A partnership between Monash University, Painaustralia and the Pharmaceutical Society of Australia has used federal government funding to develop a new opioid safety toolkit.

Australian not-for-profit Crohn’s Colitis Cure is leading a global coalition of consumer and clinician groups developing an innovative personalised care solution for people living with inflammatory bowel disease

The Albanese Government's commitment to issuing its annual Budget Process Operational Rules provides stakeholders with a historically unique insight into the complexity and challenges of its decision-making processes.

This temptation to expect rapid responses belies the complexity of the Government's decision-making processes revealed by its own Budget rule book. It takes time and a lot of formality.

The Pharmacy Guild says the federal government's own figures demonstrate that patients are currently benefiting more from the reduction in official PBS co-payments than increased dispensed quantities.

Merck has announced it is transitioning from traditional expanded polystyrene insulation to wool-pack insulation for cold-chain shipments in Australia for its life science business.

The report of a Senate inquiry into excess mortality recommends that the Government review existing vaccine compensation arrangements as a way to address hesitancy.

Researchers at the Melbourne-based WEHI have identified a potential two-in-one treatment that targets and destroys an aggressive form of brain cancer and helps the immune system develop a lasting defence against it.

MTPConnect has announced a new $28.5 million investment program supported by CSL and Roche Diagnostics for innovative small—and medium-sized enterprises developing innovative products targeting cardiovascular disease and diabetes.

The Pharmaceutical Benefits Advisory Committee will reconsider a proposal to broaden the PBS listing of immunotherapies to include current and future TGA indications.

September is Prostate Cancer Awareness Month. It is Australia’s most common cancer, with 26,000 men diagnosed every year. TrailblAZers spoke with PCFA chair Steve Callister AM about his patient journey and the importance of screening and early diagnosis.

The Albanese Government used moral suasion to resolve the IV fluid shortage caused by other jurisdictions' poor procurement practices. Health Minister Mark Butler used cautious language on the HTA Review. It was what you would expect, but what does it mean in practice?

Health Minister Mark Butler has welcomed the final tranche of PBS-listed medicines to be designated for double-dispensed quantities, but one patient organisation has urged caution.

“It is abundantly clear that the Federal Government’s watered-down vaping reforms do not go far enough to protect our children and young people," said Tasmania's Health Minister Guy Barnett.